Janus Kinase Inhibitor
Transforming Glaucoma Care With Rho Kinase Inhibitors
This activity is supported by an educational grant from Alcon Vision, LLC.
Tyrosine Kinase Inhibitors: Transforming nAMD Treatment
This activity is supported by an educational grant from EyePoint Pharmaceuticals, Inc.
Tyrosine Kinase Inhibitors and Their Role in Redefining Retinal Care
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
Filgotinib well-tolerated, efficacious for up to 8 years in rheumatoid arthritis
Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with rheumatoid arthritis, according to data published in RMD Open.
Pearl E. Grimes, MD, FAAD, honors mentor, reflects on 45 years of vitiligo advancements
ORLANDO — John Kenney Jr., MD, Lifetime Achievement Award and Lectureship recipient Pearl E. Grimes, MD, FAAD, delivered a tribute to her predecessor as she discussed the history and advancements of vitiligo.
Cycling JAKi after poor response in rheumatoid arthritis better than switching to bDMARD
For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying antirheumatic drug, according to data.
Emerging Therapies
VIDEO: JAK inhibitors in dermatology effective, ‘safer than we could have ever hoped for’
MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.
Direct switch from TNFi to tofacitinib shows ‘acceptable’ safety in psoriatic arthritis
For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.
Ivarmacitinib curbs rheumatoid arthritis symptoms, improves function through 52 weeks
A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis through 52 weeks, according to phase 3 trial results published in Annals of the Rheumatic Diseases.